Why BioNTech's Multiple Sclerosis Vaccine Could Be a Game Changer

Keith Speights, The Motley Fool

January 23, 2021 at 6:04 a.m.·3 min read

Multiple therapies are on the market today for treating multiple sclerosis (MS). In this Motley Fool Live video recorded on Jan. 13, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss BioNTech's experimental MS vaccine and why it could be a game changer in the treatment of the neurological disorder. This was using the mRNA tech indicated toward multiple sclerosis.